Industry
EUSA Pharma, Inc.
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
Failure Rate
20.0%
1 terminated/withdrawn out of 5 trials
Success Rate
66.7%
-19.9% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed trials have results
Key Signals
2 recruiting1 with results
Enrollment Performance
Analytics
Phase 1
2(50.0%)
Early Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
Early Phase 1(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT02308527Phase 2Completed
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
Role: collaborator
NCT02817997Recruiting
International Registry for Patients With Castleman Disease
Role: collaborator
NCT05316116Early Phase 1Terminated
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Role: collaborator
NCT04191421Phase 1Completed
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Role: collaborator
NCT06485947Phase 1Recruiting
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
Role: collaborator
All 5 trials loaded